← SynDRA
AMBRISENTAN
SynDRA canonical compound SYN0003780 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | EDNRB |
|---|
| Mechanism of action | Endothelin receptor antagonist |
|---|
| Indication | pulmonary arterial hypertension (PAH) |
|---|
| Disease area | pulmonary |
|---|
All known targets
- EDNRA
- EDNRB
- CYP2C19
- CYP3A4
- CYP3A5
- SLCO1B3
Mechanisms of action (all sources)
- Endothelin receptor antagonist
- EDNRB ANTAGONIST
- Endothelin receptor, ET-A/ET-B antagonist
- EDNRA ANTAGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- NR1I2
- ACHE
- ADGRF1
- HTR2B
- KCNH2
- KDR
- MAOA
- MPG
- MUTYH
- NEIL1
- NEIL2
- NTHL1
- OGG1
- OPRM1
- PDE3A
- PDE4A
- PGR
- PTGS1
- S1PR1
- SLC6A2
- SLC6A3
- SLC6A4
- SMUG1
- TBXA2R
- TDG
- HTR1A
- HRH3
- HDAC6
- CHRM2
- ADORA3
- ADRA1A
- ADRA2A
- ADRB2
- AGTR1
- APLNR
- AR
- C5AR1
- CACNA1C
- CHRM1
- CX3CR1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Endothelin Receptor Antagonists
- Endothelin Receptor Antagonist
- Antihypertensive Agents
- Cardiovascular Agents
ATC classes
- C02K · OTHER ANTIHYPERTENSIVES
Cross-references
Synonyms
- LETAIRIS
- Letairis
- LU208075
- LU 208075
- letairis
- volibris
- GSK-1325760
- GSK-1325760A
- GSK1325760
- GSK1325760A
- LU-208075
- Ambrisentan mylan
- Volibris
- Ambrisentan [INN]
- Gilead brand of ambrisentan
- BSF-208075
- BSF208075
- AMBRISENTAN, (+)-
- HW6NV07QEC
- GSK 1325760
- GSK 1325760A
- BSF 208075
- DTXCID2026282
- ambrisentanum
- Pulmonext
- (S)-ambrisentan
- (+)-ambrisentan
- (-)-ambrisentan
- RefChem:56361
- C02KX02
- C22H22N2O4
- MFCD09842330
- CAS-177036-94-1
- UNII-HW6NV07QEC
- Ambrisentan [INN:BAN:JAN]
- Ambrisentan?
- NCGC00160662-01
Reported adverse events
- Flushing
- Sinusitis
- Nasal congestion
- Headache
- Cough
- Bronchitis
- Dyspepsia
Look up AMBRISENTAN in the interactive SynDRA portal →